Production (Stage)
Proto Script Pharmaceutical Corp.
PSCR
$0.0003
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | |
|---|---|---|---|---|---|
| Revenue | 17.87% | -13.07% | -59.70% | -53.07% | 74.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.87% | -13.07% | -59.70% | -53.07% | 74.82% |
| Cost of Revenue | -3.05% | 48.94% | 7.67% | 292.52% | 535.48% |
| Gross Profit | 22.59% | -59.81% | -65.88% | -99.68% | 50.22% |
| SG&A Expenses | 71.66% | 92.22% | 123.16% | 47.02% | 0.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.88% | 79.93% | 106.08% | 68.98% | 18.72% |
| Operating Income | -85,600.00% | -260.18% | -275.52% | -439.97% | 100.17% |
| Income Before Tax | -283,800.00% | -390.56% | -439.30% | -10,458.43% | 100.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -283,800.00% | -390.56% | -439.30% | -10,458.43% | 100.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -283,800.00% | -390.56% | -439.30% | -10,458.43% | 100.17% |
| EBIT | -85,600.00% | -260.18% | -275.52% | -439.97% | 100.17% |
| EBITDA | -6,021.43% | -263.36% | -272.79% | -571.40% | 103.72% |
| EPS Basic | -- | -277.78% | -780.00% | -10,750.00% | 100.00% |
| Normalized Basic EPS | -- | -281.82% | -800.00% | -600.00% | 100.00% |
| EPS Diluted | -- | -277.78% | -780.00% | -10,750.00% | 100.00% |
| Normalized Diluted EPS | -- | -281.82% | -800.00% | -600.00% | 100.00% |
| Average Basic Shares Outstanding | -85.13% | 32.55% | -49.75% | 11.39% | 10.16% |
| Average Diluted Shares Outstanding | -85.13% | 32.55% | -49.75% | 11.39% | 10.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |